갑상선 질환 치료 세계 시장 규모는 2024년 27억 1,000만 달러로 평가되었습니다. 예측 기간 동안 34억 3,000만 달러에 달할 것으로 예상되며, 2030년까지 3.98%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.
갑상선 질환 치료 시장은 갑상선 기능 저하증, 갑상선 기능 항진증, 갑상선 결절, 갑상선암 등 갑상선 관련 질환의 유병률 증가로 인해 크게 성장하고 있습니다. 갑상선 건강에 대한 인식 증가, 조기 진단, 고급 치료 옵션의 가용성은 시장 확대에 기여하는 주요 요인입니다. 갑상선 질환에 취약한 노년층 인구 증가는 효과적인 치료 솔루션에 대한 수요를 더욱 증가시키고 있습니다. 제약회사와 의료 서비스 제공업체는 갑상선 질환 관리에 널리 사용되는 레보티록신, 메티마졸, 방사성 요오드 요법과 같은 의약품에 대한 접근성을 개선하는 데 주력하고 있습니다. 원격 의료 및 원격 모니터링을 포함한 디지털 헬스 솔루션의 통합은 적시에 진단을 받고 맞춤 치료 계획을 수립하여 환자 치료를 강화하는 데 중요한 역할을 하고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 27억 1,000만 달러 |
| 시장 규모 : 2030년 | 34억 3,000만 달러 |
| CAGR : 2025-2030년 | 3.98% |
| 급성장 부문 | 경구 |
| 최대 시장 | 북미 |
의료비 지출 증가와 바이오테크놀러지의 발전으로 갑상선 질환에 대한 새로운 치료법 개발이 가속화되고 있습니다. 병용요법, 표적 생물학적 제제, 개인 맞춤형 의료의 출현은 치료 성과와 환자 경험에 혁명을 가져오고 있습니다. 호르몬 대체요법, 고주파 소작술, 초음파 유도하 치료와 같은 최소침습적 시술의 채택이 증가하면서 치료 옵션이 확대되고 있습니다. 고감도 분석 및 영상 기술을 포함한 진단 도구의 혁신은 조기 발견과 더 나은 질병 관리를 가능하게 하고 있습니다. 제약사들의 R&D 투자 증가는 신약 발견을 촉진하고 향후 몇 년동안 시장 확대를 견인할 것으로 예상됩니다.
갑상선 치료 시장은 높은 치료비, 신흥국 시장에서의 첨단 치료 접근성 제한, 특정 갑상선 치료제의 장기적 안전성 및 유효성 우려 등의 문제에 직면해 있습니다. 갑상선 질환은 복잡하고 평생 관리해야 하는 경우가 많아 환자와 의료진 모두에게 어려움을 초래합니다. 새로운 약물과 치료법에 대한 규제 당국의 까다로운 승인 절차는 시장 진입을 지연시키고 혁신적인 치료법의 접근성을 제한할 수 있습니다. 심혈관계 합병증과 골밀도 감소 등 갑상선 호르몬 대체요법에 따른 부작용은 여전히 환자와 의료진 사이에서 우려의 대상이 되고 있습니다. 이러한 과제에도 불구하고, 정밀의료에 대한 관심 증가, 헬스케어 인프라의 확대, 제약사와 연구기관의 협력관계의 확대는 시장 성장의 기회를 창출하고 있습니다. 또한, 하시모토 갑상선염, 갑상선기능항진증과 같은 자가면역성 갑상선 질환의 유병률 증가는 첨단 면역요법 및 생물학적 치료에 대한 수요를 촉진하고 있으며, 갑상선 질환 관리의 상황을 더욱 재구성할 가능성이 있습니다.
기술 발전과 혁신적인 치료법
의료 서비스 접근성 제한
맞춤의료와 표적치료
Global Thyroid Gland Disorder Treatment Market was valued at USD 2.71 Billion in 2024 and is expected to reach USD 3.43 Billion in the forecast period with a CAGR of 3.98% through 2030. The Global Thyroid Gland Disorder Treatment Market is experiencing significant growth due to the rising prevalence of thyroid-related conditions, including hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Increasing awareness about thyroid health, early diagnosis, and the availability of advanced treatment options are key factors contributing to market expansion. The growing geriatric population, which is more susceptible to thyroid disorders, is further fueling demand for effective treatment solutions. Pharmaceutical companies and healthcare providers are focusing on improving access to medications such as levothyroxine, methimazole, and radioactive iodine therapy, which are widely used for managing thyroid conditions. The integration of digital health solutions, including telemedicine and remote monitoring, is also playing a crucial role in enhancing patient care by ensuring timely consultations and personalized treatment plans.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.71 Billion |
| Market Size 2030 | USD 3.43 Billion |
| CAGR 2025-2030 | 3.98% |
| Fastest Growing Segment | Oral |
| Largest Market | North America |
Rising healthcare expenditure and advancements in biotechnology are accelerating the development of novel treatment approaches for thyroid disorders. The emergence of combination therapies, targeted biologics, and personalized medicine is revolutionizing treatment outcomes and patient experiences. The growing adoption of hormone replacement therapy and minimally invasive procedures such as radiofrequency ablation and ultrasound-guided treatments is expanding treatment options. Innovations in diagnostic tools, including high-sensitivity assays and imaging techniques, are enabling early detection and better disease management. Increased investment in research and development by pharmaceutical companies is fostering the discovery of new drugs, which is expected to drive market expansion in the coming years.
The market faces challenges such as high treatment costs, limited accessibility to advanced therapies in developing regions, and concerns related to the long-term safety and efficacy of certain thyroid medications. The complexity of thyroid disorders, which often require lifelong management, poses difficulties for both patients and healthcare providers. Stringent regulatory approval processes for new drugs and therapies can delay market entry and limit the availability of innovative treatment options. Side effects associated with thyroid hormone replacement therapies, including cardiovascular complications and bone density loss, remain concerns among patients and medical professionals. Despite these challenges, the increasing focus on precision medicine, expansion of healthcare infrastructure, and growing collaborations between pharmaceutical companies and research institutions are creating opportunities for market growth. The rising prevalence of autoimmune thyroid diseases, such as Hashimoto's thyroiditis and Graves' disease, is also driving demand for advanced immunotherapies and biologic treatments, which could further reshape the landscape of thyroid disorder management.
Key Market Drivers
Technological Advancements and Innovative Therapies
Technological advancements and innovative therapies are significantly transforming the global thyroid gland disorder treatment market. The development of novel drug formulations, improved diagnostic tools, and advanced treatment modalities is enhancing the accuracy, efficiency, and effectiveness of thyroid disorder management. Precision medicine plays a crucial role by enabling personalized treatment approaches tailored to individual patient profiles, considering genetic, environmental, and lifestyle factors that influence thyroid function. The introduction of biologics and targeted therapies is expanding treatment options beyond traditional hormone replacement therapies, offering more effective solutions for conditions such as hypothyroidism, hyperthyroidism, and thyroid-related autoimmune disorders.
Advancements in diagnostic technologies, including high-resolution imaging, biomarker-based blood tests, and AI-powered diagnostic tools, are enabling early detection and accurate assessment of thyroid disorders. These technologies facilitate timely intervention, reducing the risk of complications associated with delayed diagnosis. The emergence of non-invasive and minimally invasive treatment options, such as radiofrequency ablation and ultrasound-guided therapies, provides patients with alternatives to surgical interventions, minimizing recovery time and associated risks. Innovations in drug delivery systems, such as extended-release formulations and novel oral delivery mechanisms, are improving patient adherence by reducing dosing frequency and enhancing drug stability.
Continuous research and development efforts are leading to groundbreaking discoveries in thyroid disorder treatment, including the exploration of regenerative medicine and gene therapy. These approaches have the potential to restore normal thyroid function by addressing the underlying causes of thyroid dysfunction rather than merely managing symptoms. Increased investment in biopharmaceutical research is accelerating the development of next-generation thyroid disorder treatments, driving market growth. The integration of digital health solutions, such as remote patient monitoring and AI-driven treatment recommendations, is further optimizing disease management, enhancing patient engagement, and supporting healthcare providers in delivering more effective and personalized care.
Key Market Challenges
Limited Access to Healthcare Services
Limited access to healthcare services poses a significant challenge to the global thyroid gland disorder treatment market, particularly in low- and middle-income countries. Many individuals suffering from thyroid disorders, such as hypothyroidism, hyperthyroidism, and thyroid nodules, struggle to receive timely diagnosis and appropriate treatment due to inadequate healthcare infrastructure. A shortage of endocrinologists and specialized healthcare professionals further limits patient access to expert consultations, leading to delays in disease management. In rural and underserved regions, medical facilities often lack the necessary diagnostic tools, such as thyroid function tests and imaging technologies, making early detection difficult. Patients in these areas may remain undiagnosed for extended periods, exacerbating symptoms and increasing the risk of severe complications such as cardiovascular diseases, osteoporosis, and metabolic disorders.
High out-of-pocket costs for consultations, diagnostic tests, and long-term medication contribute to the challenge, particularly in regions with limited healthcare insurance coverage. Many thyroid disorders require lifelong treatment, and financial constraints can lead patients to discontinue therapy, resulting in uncontrolled disease progression. The availability of essential thyroid medications, including levothyroxine and antithyroid drugs, is inconsistent in some markets due to supply chain disruptions and regulatory barriers.
Limited public awareness about thyroid disorders also hinders early diagnosis and treatment adherence. Many individuals remain unaware of common symptoms, leading to misdiagnosis or underreporting of cases. Strengthening healthcare infrastructure, expanding insurance coverage, and promoting educational initiatives are essential to overcoming these barriers and improving access to thyroid disorder treatments.
Key Market Trends
Personalized Medicine and Targeted Therapies
Personalized medicine and targeted therapies are significantly transforming the Global Thyroid Gland Disorder Treatment Market by shifting from generalized treatment approaches to patient-specific solutions. Advancements in genetic research and molecular diagnostics have enabled healthcare providers to tailor treatments based on an individual's genetic profile, disease progression, and therapeutic response. This precision is particularly beneficial in managing thyroid disorders, where hormone imbalances and autoimmune conditions necessitate specialized strategies.
In recent years, the U.S. Food and Drug Administration (FDA) has approved several targeted therapies for thyroid cancers with specific genetic mutations. For instance, in September 2024, the FDA granted traditional approval to selpercatinib (Retevmo) for adults and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer (MTC) harboring RET mutations. This approval underscores the shift towards treatments that address the molecular underpinnings of thyroid malignancies.
In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Gland Disorder Treatment Market.
Global Thyroid Gland Disorder Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: